Last reviewed · How we verify

Neupogen — Competitive Intelligence Brief

Neupogen (Filgrastim-Aafi) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Colony-stimulating factor (CSF); leukocyte growth factor. Area: Oncology.

marketed Colony-stimulating factor (CSF); leukocyte growth factor G-CSF receptor (granulocyte colony-stimulating factor receptor) Oncology Live · refreshed every 30 min

Target snapshot

Neupogen (Filgrastim-Aafi) — Amgen. Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Neupogen TARGET Filgrastim-Aafi Amgen marketed Colony-stimulating factor (CSF); leukocyte growth factor G-CSF receptor (granulocyte colony-stimulating factor receptor) 1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Colony-stimulating factor (CSF); leukocyte growth factor class)

  1. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neupogen — Competitive Intelligence Brief. https://druglandscape.com/ci/nivestym. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: